

BIOCHEMISTRY

Molecular insights into the surface-catalyzed secondary nucleation of amyloid- β_{40} ($A\beta_{40}$) by the peptide fragment $A\beta_{16-22}$

Samuel J. Bunce^{1,2*}, Yiming Wang^{3*}, Katie L. Stewart^{2,4}, Alison E. Ashcroft^{2,4}, Sheena E. Radford^{2,4†}, Carol K. Hall^{3†}, Andrew J. Wilson^{1,2†}

Understanding the structural mechanism by which proteins and peptides aggregate is crucial, given the role of fibrillar aggregates in debilitating amyloid diseases and bioinspired materials. Yet, this is a major challenge as the assembly involves multiple heterogeneous and transient intermediates. Here, we analyze the co-aggregation of $A\beta_{40}$ and $A\beta_{16-22}$, two widely studied peptide fragments of $A\beta_{42}$ implicated in Alzheimer's disease. We demonstrate that $A\beta_{16-22}$ increases the aggregation rate of $A\beta_{40}$ through a surface-catalyzed secondary nucleation mechanism. Discontinuous molecular dynamics simulations allowed aggregation to be tracked from the initial random coil monomer to the catalysis of nucleation on the fibril surface. Together, the results provide insight into how dynamic interactions between $A\beta_{40}$ monomers/oligomers on the surface of preformed $A\beta_{16-22}$ fibrils nucleate $A\beta_{40}$ amyloid assembly. This new understanding may facilitate development of surfaces designed to enhance or suppress secondary nucleation and hence to control the rates and products of fibril assembly.

INTRODUCTION

Understanding the molecular mechanisms of peptide self-assembly into amyloid fibrils is of key importance in understanding pathological disease states (1) and in designing new functional materials (2). Aberrant self-assembly of monomeric peptides or proteins into amyloid fibrils is associated with a number of degenerative conditions, notably, Alzheimer's and Parkinson's disease (1, 3), in which considerable evidence now implicates soluble oligomers as the primary cause of cellular damage (4, 5). Identifying and characterizing the structural changes that occur during peptide assembly into amyloid fibrils is essential in the quest to develop strategies to combat disease and manufacture bespoke materials (1, 6).

Peptide assembly into amyloid fibrils occurs via a complex nucleation-dependent mechanism, in which subtle changes in lowly populated states can have marked effects on the rates and products of assembly (7). Elegant work has resulted in kinetic models that are able to dissect the different contributing steps in assembly, including primary nucleation, elongation, fragmentation, and secondary nucleation (8–11). Secondary nucleation is the process whereby transient binding to a fibril surface accelerates aggregation by promoting the formation of nuclei on the fibril surface. The activation energy barrier for this phase of aggregation for $A\beta_{42}$ has been shown to be enthalpic (11) and distinct from that of other kinetic phases of assembly. Secondary nucleation is thought to be a specific process in which the effectiveness of nucleation can depend on the sequence and morphology of both the fibril and the assembling monomers, although the “rules” defining this specificity have yet to be elucidated. However, elucidating structural insights into these different steps in assembly, including

the nature of early oligomeric species, is challenging, as circular dichroism (CD), infrared, and other spectroscopic techniques generally only observe population-average data for a whole system. Single-molecule Förster resonance energy transfer (FRET) and solid-state nuclear magnetic resonance (NMR), which have uncovered clues as to the structure of toxic versus nontoxic oligomeric species (12, 13), provide information on the average properties of the different species at different times. Native ion mobility spectrometry–mass spectrometry (IMS-MS) separates ions based on shape as well as mass and charge (14) and has been used to provide insights into the population, conformation, and ligand-binding capability of individual peptide monomers and oligomers (15). By using photo-induced cross-linking (PIC), fleeting interpeptide/intrapeptide interactions may be trapped through covalent bond formation (to encode supramolecular connectivity) (16). Molecular dynamics (MD) simulations focusing on multipolypeptide systems at short time scales (<1 ms) (17) can help fill the gaps between population-average data and individual structures. Such simulations can provide insights into self-assembly events in molecular detail, allowing the earliest stages of aggregation to be visualized and the course of aggregation to be tracked in all-atom detail (18–20).

The amyloid- β peptide ($A\beta$) is a major component of the extracellular plaques observed in Alzheimer's disease (5, 21). Aggregation of $A\beta_{40/42}$ (Fig. 1A) into amyloid fibrils has been widely studied both in vitro and in vivo (22), although numerous questions remain about its structure and role in Alzheimer's disease progression (1, 22). Kinetic analysis of the sigmoid growth curves of $A\beta_{40/42}$ aggregation has enabled their assembly mechanisms to be deconvoluted into a number of microscopic steps (7, 10). Assembly begins with a lag phase, during which time monomers and small amounts of oligomers persist (7). Monomers then undergo a rearrangement step to form a nucleus (primary nucleation) from which fibrils can grow. Further aggregate growth occurs through pathways that include elongation (whereby a monomeric peptide adds onto the end of a growing fibril), fragmentation (fibrils break into two smaller aggregates, exponentially increasing growth-competent fibril ends), and surface-catalyzed

¹School of Chemistry, University of Leeds, Leeds LS2 9JT, UK. ²Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK. ³Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695-7905, USA. ⁴School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.

*These authors contributed equally to this work.

†Corresponding author. Email: s.e.radford@leeds.ac.uk (S.E.R.); hall@ncsu.edu (C.K.H.); a.j.wilson@leeds.ac.uk (A.J.W.)




Fig. 1. Co-aggregation of Aβ₁₆₋₂₂ and Aβ₄₀ results in accelerated aggregation kinetics for Aβ₄₀. (A) Primary sequence of Aβ₁₆₋₂₂ and Aβ₄₀, including the groups at each terminus. The central recognition motif KLVFF is highlighted in purple. (B) ThT fluorescence assays showing that the aggregation rate of Aβ₄₀ increases as the ratio of Aβ₁₆₋₂₂ to Aβ₄₀ is increased (with the total peptide concentration held constant at 40 μM). (C) Simulation snapshots of the aggregation of six Aβ₄₀ monomers into a β-sheet-rich hexamer at an Aβ₄₀ concentration of 5 mM. At the start of the simulation (0 μs), all the peptides are in random coils, but as the simulation progresses, they aggregate into antiparallel, in-register β sheets (104 μs). This oligomer then unfolds, losing some of its β-sheet structure (230 μs) before a rearrangement in which the β sheets rearrange, forming a stable fibril, with each Aβ₄₀ peptide containing three β strands (621 μs) engaged in parallel intermolecular hydrogen bonding.

secondary nucleation (whereby nucleation is catalyzed on the fibril surface) (23). Using MD simulations, the energy landscape of Aβ₄₀ oligomer formation has also been modeled, demonstrating the different kinetic pathways that underlie the formation of prefibrillar and nonfibrillar oligomers (17). For Aβ₄₀, primary nucleation has been shown to be a slower process than secondary pathways such that surface-catalyzed secondary nucleation events dominate the growth rate of fibrils (10). Under quiescent conditions, the contribution of fibril fragmentation to the growth of fibrils has been shown to be negligible (9). Co-aggregation processes (i.e., where two different peptide sequences interact during aggregation but need not co-assemble) can result in more complex kinetics due to the possibility of the sequences interacting with each other to modulate aggregation (24, 25). Such a situation may occur in vivo wherein multiple sequences of different lengths of Aβ are formed (26).

Here, we combine fluorescence assays, electrospray ionization (ESI)-IMS-MS, and PIC experiments to study the structural mechanism of co-assembly of the peptide fragment Aβ₁₆₋₂₂ (Fig. 1A), which contains the “core recognition motif” KLVFF (27) of Aβ₄₀, with the parent Aβ₄₀ sequence. Aβ₁₆₋₂₂ has been shown to form fibrils with an in-register, antiparallel orientation at neutral pH (28) and has been proposed to assemble via an intermediate with out-of-register β-sheet alignment before reaching the final in-register fibril structure (29). The rate of Aβ₁₆₋₂₂ aggregation is dependent on peptide concentration and ionic strength (29–31). Discontinuous MD (DMD) has also shown that the nucleation-dependent aggregation process of Aβ₁₆₋₂₂ proceeds from a random coil configuration to form multilayer β-sheet fibrils, with an in-register antiparallel β-sheet orientation, in accordance with the experimental data (32). Here we show, using fluorescence quenching assays, that Aβ₁₆₋₂₂ aggregates more rapidly than Aβ₄₀ and that Aβ₁₆₋₂₂ fibril formation then

increases the aggregation rate of Aβ₄₀ through a surface-catalyzed secondary nucleation mechanism, mirroring the behavior observed in kinetic analyses of Aβ_{40/42} aggregation (9, 10) and their co-aggregation (24). Using DMD simulations, we also show that the preformed Aβ₁₆₋₂₂ fibrils increase the early-stage aggregation rate of Aβ₄₀ but that the monomeric Aβ₁₆₋₂₂ peptides do not, supporting secondary nucleation as the mechanism of enhanced Aβ₄₀ aggregation by Aβ₁₆₋₂₂. These experimentally validated simulations portray the structural mechanism of surface-catalyzed nucleation. This new understanding may pave the way to the generation of surfaces able to enhance or suppress assembly and may inform effective design of ligands that modulate therapeutically important amyloid assembly.

RESULTS

Aβ₁₆₋₂₂ increases the aggregation rate of Aβ₄₀

To determine whether the presence of Aβ₁₆₋₂₂ affects the aggregation rate of Aβ₄₀, we synthesized or recombinantly expressed the peptides (see Materials and Methods, Supplementary Materials, and figs. S1 and S2), purified them, and mixed them in different ratios at a constant total peptide concentration of 40 μM. The rate of aggregation was then measured using the fluorescence of thioflavin-T (ThT; Fig. 1B, Materials and Methods, and fig. S3). Initial experiments showed the expected sigmoid increase in ThT fluorescence for Aβ₄₀ (7, 10, 33), indicating the assembly of this peptide into amyloid fibrils (Fig. 1B). While Aβ₁₆₋₂₂ formed fibrils under the conditions used based on transmission electron microscopy (TEM) images (Fig. 2F and fig. S4), as expected (16), ThT fluorescence did not increase over 12 hours (Fig. 1B), indicating that the fibrils formed either are unable to bind ThT or do not enhance its fluorescence when bound; rotational immobilization of ThT is required for its fluorescent




Fig. 2. Aggregation kinetics of Aβ₁₆₋₂₂ are unaffected by the presence of Aβ₄₀. (A) Schematic showing the principle behind the fluorescence quenching assay used to determine the aggregation rate of Aβ₁₆₋₂₂. (B) As self-assembly occurs, the TAMRA-labeled peptides [40 μM total peptide containing 5% (w/w) TAMRA-Ahx-Aβ₁₆₋₂₂] are sequestered into the fibril structure. This brings the fluorophores into proximity, resulting in fluorescence quenching. (C) Aggregation of Aβ₁₆₋₂₂ [containing 5% (w/w) TAMRA-Ahx-Aβ₁₆₋₂₂] and Aβ₄₀ at a 1:1 mol/mol ratio (40 μM total peptide concentration). A single transient, which is the median of three replicates measured, is shown. (D and E) Sedimentation and separation of the pellet and supernatant of the 1:1 mixed system and analysis of the fractions using ESI-MS after 1 hour indicate that Aβ₄₀ is present in the (D) supernatant and in only very small amounts within the (E) pellet. (F) Under these conditions, fibrils of Aβ₁₆₋₂₂ are present after 5 min of incubation. Scale bars, 500 nm.

enhancement when bound to amyloid fibrils (34). Other amyloid dyes (NIAD-4, Congo Red, and ANS) were screened against Aβ₁₆₋₂₂ fibrils; however, none produced a signal with which to perform kinetic assays. The increase in ThT signal in the peptide mixture thus reports on the aggregation rate of Aβ₄₀ and how this is affected by the presence of Aβ₁₆₋₂₂. The experiments in Fig. 1B show that, at a constant peptide concentration of 40 μM, as the molar ratio of Aβ₁₆₋₂₂ to Aβ₄₀ is increased, the apparent aggregation rate of Aβ₄₀ also increases. Competition between the increased rate of Aβ₄₀ aggregation as Aβ₁₆₋₂₂ concentration increases and the decreased rate of aggregation of Aβ₄₀ as its concentration correspondingly decreases results in maximal apparent rate enhancement at a 1:1 molar ratio of the two peptides (Fig. 1B). We accounted for this effect by measuring, in parallel, the $t_{1/2}$ (the time at which the growth curve reaches 50% amplitude) value of aggregation of Aβ₄₀ alone at each concentration and comparing the $t_{1/2}$ values with and without Aβ₁₆₋₂₂ added (see fig. S3). These data show that the effect saturates as would be expected for secondary nucleation events involving binding to the fibril surface.

To characterize the extent to which Aβ₄₀ aggregation is accelerated by the presence of Aβ₁₆₋₂₂, we calculated the half-time ($t_{1/2}$) for each peptide mixture and normalized to the half time for the equivalent concentration of Aβ₄₀ alone (fig. S3). The results revealed a marked, and titratable, effect of the presence of Aβ₁₆₋₂₂ on the aggregation rate of Aβ₄₀, demonstrating an interaction between the two peptides that accelerates the rate of assembly.

Aβ₁₆₋₂₂ aggregates more rapidly than Aβ₄₀ and is unaffected by the presence of Aβ₄₀

As the assembly kinetics of Aβ₁₆₋₂₂ could not be measured using any of the amyloid dyes surveyed at the concentrations used here, a fluorescence quenching assay was developed to determine whether Aβ₁₆₋₂₂ aggregates more or less rapidly than Aβ₄₀ (Fig. 2A). Similar assays have been previously used to monitor the aggregation rates of Aβ₄₀ and Aβ₄₂ (35), with fluorescence quenching reporting on labeled monomers coming into mutual proximity as oligomers (or fibrils) form. For these assays, Aβ₁₆₋₂₂ N-terminally labeled with tetramethylrhodamine (TAMRA) was synthesized, including a

6-aminohexanoic acid linker (Ahx) to limit disruption to the native fibril structure that might arise due to the bulky fluorophore (TAMRA-Ahx- $A\beta_{16-22}$; Supplementary Materials and figs. S1 and S4). When incubated in isolation, a 5% (w/w) TAMRA-Ahx- $A\beta_{16-22}$:95% $A\beta_{16-22}$ mixture (20 μ M) resulted in a rapid decrease in fluorescence intensity followed by a slower phase that plateaued after 1 hour (Fig. 2B). In the presence of $A\beta_{40}$ [1:1 (mol/mol) ratio, 40 μ M total peptide concentration, and 2% (v/v) dimethyl sulfoxide (DMSO)], no difference in the rate of fluorescence decrease was observed, indicating that the presence of $A\beta_{40}$ has no effect on $A\beta_{16-22}$ aggregation (Fig. 2C). Analysis of these samples by negative-stain TEM showed the presence of fibrils after only 5 min (Fig. 2F). Sedimentation of the mixed system by centrifugation after 1 hour demonstrated that $A\beta_{40}$ was present mainly in the supernatant (Fig. 2, D and E). These results demonstrate that $A\beta_{16-22}$ aggregates rapidly to form amyloid-like fibrils, while $A\beta_{40}$ remains soluble as monomers/oligomers. Thus, although the rate of $A\beta_{40}$ aggregation is increased by the presence of $A\beta_{16-22}$, limited or no co-assembly between the two peptides into fibrils was observed. By contrast, $A\beta_{16-22}$ aggregation is unaffected by the presence of $A\beta_{40}$. $A\beta_{40}$ fibrils have been shown to adopt a parallel in-register structure involving most of the polypeptide backbone (21, 36), while $A\beta_{16-22}$ has been shown to form an antiparallel β -stranded amyloid structure (28, 29). This structural incompatibility could account for the absence of co-assembly because

such a structure would be less stable compared with homomeric assemblies. Furthermore, the more rapid fibril assembly of $A\beta_{16-22}$ in comparison to $A\beta_{40}$ disfavors co-assembly on kinetic grounds.

Monomeric $A\beta_{16-22}$ can interact with monomeric and oligomeric $A\beta_{40}$ through the self-recognition motif KLVFF

To determine whether $A\beta_{16-22}$ and $A\beta_{40}$ interact transiently in the early stages of assembly, we performed native ESI linked to IMS-MS (see Materials and Methods). This soft ionization technique has been used to identify and structurally characterize amyloid oligomers that formed from several different proteins and peptides (14, 15). Under the conditions used here, ESI-IMS-MS immediately following mixing revealed that $A\beta_{40}$ copopulates a number of oligomers, ranging from monomers to pentamers (Fig. 3B, white, and table S1), consistent with previous results (33). When incubated with $A\beta_{16-22}$, heteromolecular oligomers were observed (Fig. 3B, light blue), along with homomolecular oligomers of $A\beta_{40}$ (Fig. 3A, white). Notably, $A\beta_{16-22}$ homomolecular oligomers were not observed. The heteromolecular oligomers correspond to multiple $A\beta_{16-22}$ monomers that bound to either an $A\beta_{40}$ monomer or dimer (table S1). Collision cross-section (CCS) estimations from the ESI-IMS-MS analysis of the $A\beta_{40}$ species in the presence or absence of $A\beta_{16-22}$ indicate no discernible difference in the gas-phase cross-section of $A\beta_{40}$,




Fig. 3. $A\beta_{16-22}$ can interact with $A\beta_{40}$ monomers and dimers. (A) Native ESI-IMS-MS drift-scope images of $A\beta_{40}$ indicate the presence of multiple oligomeric species of $A\beta_{40}$ (white numbers). (B) When mixed at a 1:1 mol/mol ratio with $A\beta_{16-22}$ (yellow numbers), a number of heteromeric species are observed (light blue numbers) immediately following mixing. The oligomer size is given (1, 2, 3, etc.), with the charge state in superscript. (C) DMD simulation showing the percent β sheet formed by $A\beta_{40}$ during aggregation in the absence (black) or presence (red) of $A\beta_{16-22}$. (D) Energy contact map between one monomer of $A\beta_{16-22}$ and one of $A\beta_{40}$ scaled by energy (bar shown alongside), showing that residues 17 to 20 (LVFF) and 31 to 34 (ILGL) form the strongest interactions. (E) Co-aggregation can have differing effects on the primary nucleation of each peptide, depending on whether the mixed oligomers formed can progress to form mixed fibrils or are off-pathway and take no further part in the aggregation reaction. Circles represent monomers and blocks represent fibrils, with $A\beta_{16-22}$ and $A\beta_{40}$ in red and blue, respectively. Adapted from (24).

implying that a conformational change in monomer or oligomer structure is unlikely to be the provenance for the $A\beta_{16-22}$ -driven increase in the $A\beta_{40}$ aggregation rate (fig. S5). Despite attempts to capture the interaction experimentally by PIC using a diazine-labeled $A\beta_{16-22}$ ($A\beta_{16-22}^*$; see the Supplementary Materials for synthesis, scheme S1, and fig. S1), the site of interaction could not be verified (fig. S6 and table S2) likely due to the low percentage of any heterodimers present (as assessed by total ion count, $1.0 \pm 0.5\%$) and the lower solution concentration of $A\beta_{16-22}$ arising as a consequence of its rapid aggregation.

To further assess the nature of the interactions between $A\beta_{16-22}$ and $A\beta_{40}$, we performed DMD simulations (see Materials and Methods). To evaluate the role of interactions between $A\beta_{40}$ and $A\beta_{16-22}$ monomers (covered in this section), it was first necessary to perform DMD simulations on the aggregation of $A\beta_{40}$ alone (Fig. 1C) and then a 1:1 mixture of the $A\beta_{16-22}$ and $A\beta_{40}$ peptide sequences at $C_{\text{peptide}} = 5 \text{ mM}$ (Fig. 3C). These co-aggregation simulations starting from monomeric peptides are further discussed in the course of our analyses to rule out co-assembly (see below), and then we describe DMD analyses on the effect of $A\beta_{16-22}$ fibrils on $A\beta_{40}$ aggregation (see below). Simulations performed on six monomers of $A\beta_{40}$ (Fig. 1C) showed that the initially unstructured peptides assemble and adopt a metastable oligomer structure by $104 \mu\text{s}$ (Fig. 1C); this structure comprises antiparallel intramolecular β strands linked by disordered regions assembled into antiparallel intermolecular sheets, with β strands stacked perpendicular to the long axis. During this oligomerization stage, the peptide conformation is similar to that ob-

served by Zheng *et al.* (17). As the simulation proceeds, this oligomer loses some β -sheet content ($t = 230 \mu\text{s}$; Fig. 1C). By the end of the simulation ($621 \mu\text{s}$), peptides in oligomers undergo structural rearrangement from antiparallel β -strand conformations to the parallel β -sheet conformation observed for $A\beta_{40}$ fibrils (Fig. 1C) (37). Simulations of the peptide mixtures did not show an accelerating effect of $A\beta_{16-22}$ monomers on the aggregation rate of $A\beta_{40}$ (see Fig. 3C and later). However, interactions between the two peptides were observed, consistent with the ESI-MS results in Fig. 3. From the DMD data, an energy contact map between the monomeric $A\beta_{16-22}$ and $A\beta_{40}$ peptides was calculated (Fig. 3D). The contact map indicated that $A\beta_{16-22}$, specifically residues 18 to 20 (VFF), interacts strongly with residues 19 to 21 and 32 to 35 of $A\beta_{40}$ (FFA and IGLM, respectively), consistent with experimental data previously reported, which indicate that KLVFF is a “self-recognition element” (27). Such an interaction between $A\beta_{16-22}$ and $A\beta_{40}$ oligomers, however, does not result in an acceleration of aggregation (Fig. 3C), implying that these mixed and low-abundance oligomers represent transient species that do not affect the rate of assembly (Fig. 3E).

$A\beta_{16-22}$ fibrils have a larger effect on the aggregation rate of $A\beta_{40}$ than $A\beta_{16-22}$ monomer

To determine whether rapidly formed $A\beta_{16-22}$ fibrils are the causative agents of the enhanced rate of $A\beta_{40}$ aggregation in the mixed samples (Fig. 1B), we assessed the effect of preformed $A\beta_{16-22}$ fibrils on $A\beta_{40}$ aggregation. These experiments (Fig. 4A) showed that the presence of $A\beta_{16-22}$ fibrils increases the rate of aggregation of $A\beta_{40}$




Fig. 4. $A\beta_{16-22}$ fibrils increase the aggregation rate of $A\beta_{40}$ to a greater extent than $A\beta_{16-22}$ monomers. (A) Increased concentrations (% w/w) of $A\beta_{16-22}$ fibrils were added to $A\beta_{40}$ monomers (as shown in the key), and the aggregation rate was measured by ThT fluorescence. (B) Direct comparison of the effect of $A\beta_{16-22}$ monomers (i.e., taken straight from a DMSO stock) and $A\beta_{16-22}$ fibrils on $A\beta_{40}$ aggregation. (C) Effect of sonicating the $A\beta_{16-22}$ fibrils on the $A\beta_{40}$ aggregation rate shows little effect compared with the data shown in (A) (see text for details). (D) Plots of the percent β sheet formed by $A\beta_{40}$ in the absence (blue) or presence of preformed two (black), three (red), or four (green) β -sheet $A\beta_{16-22}$ fibrils, determined using DMD, showing that an increased $A\beta_{16-22}$ fibril size increases the rate of $A\beta_{40}$ aggregation. (E) During co-aggregation experiments, both elongation and surface-catalyzed mechanisms can occur; each has a different effect on the rate of assembly of each peptide (the same notation is used as in Fig. 3E, with circles representing monomers, blocks representing fibrils, and $A\beta_{16-22}$ and $A\beta_{40}$ in red and blue, respectively). Adapted from (24).

in a fibril concentration–dependent manner (Fig. 4A), and addition of $A\beta_{16-22}$ fibrils had a larger effect on the aggregation rate compared with the addition of monomeric (i.e., taken straight from a DMSO stock) $A\beta_{16-22}$ (Fig. 4B). This suggests that aggregation is enhanced either by cross-seeding (i.e., by adding $A\beta_{40}$ directly to the ends of $A\beta_{16-22}$ fibrils) or by secondary nucleation of $A\beta_{40}$ on the $A\beta_{16-22}$ fibril surface (Fig. 4E). Sonication of fibrils fragments them, leading to a higher concentration of fibril ends. Hence, should elongation dominate the rate of fibril formation, sonication should markedly increase the rate of fibril growth. Comparison of the effects of unsonicated fibrils (fewer ends) with the same fibrils fragmented by sonication (Fig. 4C and see fig. S4 for TEM analyses) indicated that elongation was not dominant (Fig. 4C), because the average $t_{1/2}$ for sonicated fibrils (6.2 ± 1.0 hour) is similar to that of its unfragmented counterpart (7.2 ± 0.7 hours). Together, the results demonstrate that the presence of rapidly formed $A\beta_{16-22}$ fibrils enhances aggregation of $A\beta_{40}$ in peptide mixtures by secondary nucleation, despite the presence of small amounts of mixed oligomers (as demonstrated by the ESI-IMS-MS experiments).

DMD simulations of the aggregation of six $A\beta_{40}$ peptides were also performed in the presence of preformed $A\beta_{16-22}$ fibrils of different sizes (two, three, and four β sheets) at an $A\beta_{40}$ concentration of 1 mM to model the dynamic process of the secondary nucleation event. The results (Fig. 4D) showed that the largest $A\beta_{16-22}$ fibril (i.e., four β sheets; green trace in Fig. 4D) led to the largest increase in the rate of β -sheet formation by $A\beta_{40}$. Given that the presence of $A\beta_{16-22}$ monomers had no observable effect on $A\beta_{40}$ assembly (Fig. 3C), these simulations are thus qualitatively concordant with the experimental findings that the fibrillar structure of $A\beta_{16-22}$ is the domi-

nant influence on the aggregation rate of $A\beta_{40}$. Such behavior is consistent with that observed for $A\beta_{40/42}$ co-aggregation for which a kinetic model has been established (24).

$A\beta_{40}$ and $A\beta_{16-22}$ form distinct homomolecular fibrils

The peptide composition of the final fibril structure(s) represents a further means to discern the difference between surface-catalyzed secondary nucleation and co-assembly exploiting fibril ends. A surface-catalyzed mechanism would most likely produce homomolecular fibrils of $A\beta_{40}$, as once they have formed on the $A\beta_{16-22}$ fibril surface, the $A\beta_{40}$ nuclei would dissociate and form pure $A\beta_{40}$ fibrils. In contrast, co-assembly involving fibril ends should result in mixed fibrils, in which $A\beta_{16-22}$ seeds are segmentally separated from fibril regions containing $A\beta_{40}$ monomers.

Negative-stain TEM images taken at the end of the aggregation reaction showed $A\beta_{40}$ fibrils with similar gross morphology when incubated in isolation or co-aggregated with $A\beta_{16-22}$ (Fig. 5, A and B). Similarly, quantitation of ThT fluorescence at the end-point of aggregation in mixed samples and quantitation of the same concentration of $A\beta_{40}$ incubated alone were indistinguishable (fig. S3), supporting the hypothesis that homomolecular $A\beta_{40}$ fibrils are formed at the end of the assembly reaction. Last, PIC was used to explore whether homo- or heteromolecular fibrils had formed (Fig. 5C and Materials and Methods). To perform PIC experiments, a diazirine label was placed on F20 of $A\beta_{16-22}$ ($A\beta_{16-22}^*$) (16). Control experiments demonstrated that $A\beta_{16-22}^*$ has a similar effect on the rate of $A\beta_{40}$ aggregation as its unmodified counterpart (fig. S3). PIC experiments performed 5 min and 24 hours after initiating assembly failed to detect cross-links between $A\beta_{16-22}^*$ and $A\beta_{40}$ (Fig. 5C, fig. S6,




Fig. 5. $A\beta_{16-22}$ and $A\beta_{40}$ do not co-assemble during co-aggregation. Negative-stain TEM analysis of $A\beta_{40}$ incubated for 24 hours in the (A) absence or (B) presence of $A\beta_{16-22}$. Scale bars, 200 nm. (C) PIC of mixtures of diazirine-labeled $A\beta_{16-22}$ ($A\beta_{16-22}^*$) and $A\beta_{40}$ incubated for 24 hours and then irradiated for 30 s. Only homomolecular $A\beta_{16-22}^*$ cross-links are observed, indicating that the fibrils are not copolymerized at the end of the reaction (the inset depicts the mechanism of PIC of the diazirine group). (D) DMD simulation snapshots of co-aggregation of $A\beta_{40}$ (blue) and $A\beta_{16-22}$ (red) indicate that separate homomolecular oligomers are formed at $t = 202 \mu\text{s}$.

and table S2). Instead, all identifiable cross-links were consistent with intermolecular/intramolecular $A\beta_{16-22}^*$ or solvent adducts, as previously identified in $A\beta_{16-22}^*$ -containing fibrils by Preston *et al.* (16), indicating that co-assembly into fibrils either is very rare and cannot be detected despite the sensitivity of ESI-MS or does not occur.

To provide a molecular image of co-assembly, we further analyzed the DMD simulations in which six $A\beta_{40}$ and six $A\beta_{16-22}$ monomers were mixed and their aggregation behavior was monitored versus time at $C_{\text{peptide}} = 5 \text{ mM}$ (Fig. 5D). The simulations showed that in the early stages of assembly ($t = 0.6 \mu\text{s}$), a mixture of monomeric and oligomeric $A\beta_{40}$ was present. As the simulation progressed ($t = 57 \mu\text{s}$), all $A\beta_{40}$ peptides coalesced into one β -sheet-rich oligomer, with $A\beta_{16-22}$ intercalated within the structure. Throughout the simulation, monomeric $A\beta_{16-22}$ was observed to bind transiently to other monomeric $A\beta_{16-22}$ peptides or the KLVFF motif of $A\beta_{40}$, in accordance with the data presented above. Last, at the end of the simulation ($t = 202 \mu\text{s}$), the peptides form distinct oligomeric domains, with $A\beta_{40}$ and $A\beta_{16-22}$ forming separate sheets.

$A\beta_{40}$ oligomer dynamics on the surface of $A\beta_{16-22}$ fibrils

To obtain a molecular image of the process of secondary nucleation, we performed DMD simulations, in which six $A\beta_{40}$ monomers were mixed with preformed fibrils of $A\beta_{16-22}$ at $C_{A\beta_{40}} = 5 \text{ mM}$ (Fig. 6A). At the early stage of the simulation ($t = 0.29 \mu\text{s}$), three $A\beta_{40}$ peptides were present in an oligomer: One $A\beta_{40}$ peptide was associated at the end of the fibril, and the remaining two $A\beta_{40}$ peptides were elongated across the fibril surface. At this stage ($t = 0.29 \mu\text{s}$), the $A\beta_{40}$ peptides

in the oligomer and on the surface were observed to adopt a predominantly random coil conformation with small amounts of β -strand structure [note that an elongated monomeric structure was also observed in simulations performed by Barz and Strodel (19) in exploring the secondary nucleation of $A\beta_{42}$ on the surface of $A\beta_{11-42}$]. The β sheets were next observed to act as templates for peptides present in a random coil conformation ($1.93 \mu\text{s}$) and to pull them more fully to the fibril surface. Thus, as the simulation progressed, the $A\beta_{40}$ peptides remaining in solution were recruited by those on the fibril surface. Once the oligomer became fully associated with the fibril surface, the amount of β -sheet structure in the surface-associated oligomer increased ($t = 7.7 \mu\text{s}$); antiparallel β strands formed via inter- and intramolecular hydrogen bonding, leading to sheet formation consistent with the early stages observed in the simulations performed for $A\beta_{40}$ alone ($t = 104 \mu\text{s}$; Fig. 1C). Last, the surface-associated $A\beta_{40}$ peptides were joined in an ordered oligomer ($t = 29.0$ and $77.7 \mu\text{s}$). Related “bind and reorganize” processes for secondary nucleation were observed in simulations performed by Schwierz *et al.* (38) using $A\beta_{9-40}$ as a model. As noted above, $A\beta_{40}$ peptides attached both to the lateral surface and to the end of the $A\beta_{16-22}$ fibril during the simulation, with the $A\beta_{40}$ C-terminal region attaching more frequently to the lateral surface of the fibril than to the fibril ends at $C = 5 \text{ mM}$ (fig. S7). To assess the consistency of the results, we repeated the simulation three times; two of the three independent runs gave results similar to those described above, while for the final run, a greater number of associations to the fibril end were observed. Collectively, these results provide molecular images of surface-catalyzed nucleation,




Fig. 6. $A\beta_{16-22}$ fibrils catalyze $A\beta_{40}$ assembly through secondary surface nucleation. (A) Simulation snapshots of the process by which $A\beta_{16-22}$ fibrils (red) increase the aggregation rate of $A\beta_{40}$ (blue) through a surface-catalyzed secondary nucleation. (B) A schematic description of the mechanism is also included, with $A\beta_{40}$ in blue and $A\beta_{16-22}$ in red.

in which a random coil peptide is catalytically converted into a β -sheet fibrillar structure on a fibril surface.

DISCUSSION

In this work, we used ESI-MS, PIC, and DMD to study the co-assembly mechanism of $A\beta_{16-22}$ and $A\beta_{40}$ into amyloid, demonstrating the power of using integrated approaches to study structural determinants of molecular assembly processes. We show that mixed $A\beta_{16-22}/A\beta_{40}$ heteromeric oligomers form but that these are transient and lowly populated ($\sim 1\%$) and do not significantly affect the rate of aggregation. In contrast, $A\beta_{16-22}$ has a high propensity to self-associate into homomolecular fibrils, and these fibrils accelerate $A\beta_{40}$ assembly by monomer/oligomer interactions through secondary nucleation at the fibril surface. Recent modeling of amyloid assembly kinetics has revealed the importance of primary nucleation, secondary nucleation, and fibril elongation in fibril growth mechanisms (7, 10, 23). Notably, a kinetic model has been described for the co-aggregation of $A\beta_{40/42}$ (24). The experimental data presented here for co-aggregation of $A\beta_{16-22}$ and $A\beta_{40}$ qualitatively agree with this model, whereas our DMD simulations illustrate that while all primary/secondary nucleation and elongation processes occur simultaneously, secondary nucleation is the dominant process in $A\beta_{40}$ fibril formation kinetics during co-assembly with $A\beta_{16-22}$, which is consistent with the findings for the self-assembly mechanism of $A\beta_{40}$ observed previously (9, 10, 24). Moreover, $A\beta_{40}$ assembly intermediates on the surface of $A\beta_{16-22}$ fibrils resemble those formed spontaneously in solution for $A\beta_{40}$ alone, implying that the fibril surface catalyzes the assembly reaction without modifying the molecular mechanism, at least for the simulations performed here. Whether this holds for other sequences and co-assembly reactions will require further exploration (notably, which features of a fibril and the assembling monomer determine compatibility with secondary nucleation from a fibril surface).

Overall, the current study thus serves to emphasize the marked differences in aggregation behavior that are observed during co-aggregation compared to homomolecular self-assembly and underscores the need to use multiple methods to understand aggregation mechanisms in molecular detail. Significant current interest centers on characterizing distinct molecular steps leading to amyloid fibril formation, with secondary nucleation considered as playing a key role in causing toxicity (11, 39). Recently, kinetic analyses have been augmented by mapping the free-energy landscapes defining different microscopic phases in the aggregation pathway (11), providing insight to facilitate development of strategies that modulate the thermodynamically distinct surface-monomer interactions characteristic of secondary nucleation. However, to design therapeutically useful modulators of amyloid aggregation requires that this understanding is complemented with structural insights of the molecular recognition between fibrils and monomers, set within the context of other interactions occurring during aggregation (e.g., monomer-nuclei interactions). We have shown here that $A\beta_{40}$ monomers and oligomers dock onto the fibril surface, which catalyzes the assembly of antiparallel strand formation in close situ to the parent $A\beta_{16-22}$ fiber. Whether this is the end-point product or further reorganization is required to generate the final amyloid structure requires further study (longer simulation time). In this context, metastable amyloid structures have been observed for the Iowa mutant of $A\beta_{40}$ using solid-state NMR, in which antiparallel fibrils were observed as trapped

intermediates in the assembly process to the final all-parallel fibril structure (40).

Together, the results demonstrate that kinetic analyses and theory together with MD provide a powerful arsenal and capability to visualize secondary nucleation in structural and kinetic detail. Such approaches may allow informed targeting of this process to either prevent or accelerate secondary nucleation for therapeutic purposes and peptide material assembly. Co-aggregation adds an additional layer of complexity in understanding molecular assembly yet represents an opportunity to manipulate these supramolecular assembly processes, as demonstrated here for the model system involving $A\beta_{16-22}$ and $A\beta_{40}$. Evidently, $A\beta_{40}$ shows a propensity to aggregate via secondary nucleation from its own fibril surface or that of other peptide sequences, as shown here for fibrils of $A\beta_{16-22}$. Hence, this work begins to address the molecular recognition events required for secondary nucleation to occur on a fibril surface and may inform strategies to modulate the aggregation of $A\beta_{40}$ under conditions in which secondary nucleation dominates fibril growth.

MATERIALS AND METHODS

Synthesis of *N*-Fmoc TFMD-Phe and $A\beta$ peptides

N-Fmoc TFMD-Phe was synthesized using the method described by Smith *et al.* (41) and further minor changes in protecting group (scheme S1). $A\beta_{16-22}$, TAMRA-Ahx- $A\beta_{16-22}$, and $A\beta_{16-22}^*$ were synthesized via both automated and manual solid-phase peptide synthesis and dissolved into DMSO stock solutions before use (fig. S1). $A\beta_{40}$ was synthesized recombinantly using the method of Walsh *et al.* (42) and modifications by Stewart *et al.* (43). To ensure that $A\beta_{40}$ was monomeric before use, the peptide was purified by size exclusion chromatography, lyophilized, and stored at -4°C (fig. S2).

ThT fluorescence assays

Samples were prepared in a 96-well nonbinding plate (Corning Costar 3881, Corning Life Sciences, Amsterdam, the Netherlands) sealed with clear sealing film (BMG Labtech, Aylesbury, Bucks, UK) and were incubated in a FLUOstar OPTIMA plate reader (BMG Labtech, Aylesbury, Bucks, UK) for 20 hours at 37°C without agitation. Samples had a volume of $95\ \mu\text{l}$ containing $10\ \mu\text{M}$ ThT in $100\ \text{mM}$ ammonium bicarbonate (pH 7.4) and a final concentration of 1% (v/v) DMSO. For seeding experiments, $A\beta_{16-22}$ was incubated at $50\ \mu\text{M}$ for at least 24 hours in the same buffer as described above, with the presence of fibrils confirmed by TEM (described below). Before the assay, the fibrils were probe-sonicated for 5 s at 22% amplitude to generate “seeds.” The ThT experiments used excitation and emission filters of 430 and 485 nm. Each ThT experiment shown was repeated in independent assays on three different occasions, with the traces shown in this work being representative of all repeats.

Transmission electron microscopy

TEM images were taken at the end of each experiment by removing $5\ \mu\text{l}$ from the necessary well and incubating this sample on carbon-formvar grids for 30 s before staining with 2% (w/v) uranyl acetate solution for an additional 30 s, as described by Preston *et al.* (27). Images were taken on a JEM-1400 (JEOL Ltd., Tokyo, Japan) or a Tecnai F12 TEM. Images were taken on a JEM-1400 (JEOL Ltd., Tokyo, Japan) or a Tecnai T12 (FEI, Hillsboro, OR, USA) TEM. Images were taken using either an ATM charge-coupled device (CCD) camera or a Gatan UltraScan 1000 XP (994) CCD camera (JEM-1400) or an

UltraScan 100XP (994) CCD camera (Tecna F12). Once taken, images were processed using ImageJ [National Institutes of Health (NIH)].

General sedimentation protocol

Samples were taken at the desired time point and centrifuged (20 min, 14,000g, 4°C). Each sample was then separated into pellet and supernatant fractions, lyophilized overnight, and disaggregated in hexafluoroisopropanol (HFIP) for at least 2 hours. HFIP was removed under a stream of N₂, and the peptides were taken up in DMSO before analysis by high-resolution MS (Bruker HCT ion-trap MS).

Fluorescence quenching assays

Wild-type Aβ_{16–22} was spiked with 5% (w/w) TAMRA-Ahx-Aβ_{16–22} and incubated either in isolation or at a 1:1 ratio with Aβ₄₀ (total peptide concentration, 40 μM) in 100 mM ammonium bicarbonate buffer (pH 7.4) with a final concentration of 2% (v/v) DMSO. Samples were placed in quartz cuvettes and analyzed using a temperature-controlled fluorimeter at 37°C. Time points were taken every 30 s for the duration of the experiment, and TEM images (as described above) were taken at the end of each experiment to ensure the presence of fibrils. The TAMRA fluorophore was excited at 520 nm, and emission was recorded at 600 nm to reduce the inner filter effect.

ESI-IMS-MS analysis

All samples were prepared as described above and left to incubate at 37°C without agitation for 5 min. A SYNAPT HDMS quadrupole time-of-flight MS (Micromass UK Ltd., Waters Corp., Manchester, UK), equipped with a TriVersa NanoMate (Advion Biosciences, Ithaca, NY, USA) automated nano-ESI interface, was used in this study. The instrument has a traveling-wave IMS device situated in between the quadrupole and the time-of-flight analyzers, as described in detail elsewhere. Samples were analyzed by positive ionization nano-ESI, with a capillary voltage of 1.4 kV and a nitrogen-nebulizing gas pressure of 0.8 psi. The following instrumental parameters were set: cone voltage, 60 V; source temperature, 60°C; backing pressure, 4.7 mbar; ramped traveling speed, 7 to 20 V; traveling wave speed, 400 m s⁻¹; IMS nitrogen gas flow, 20 ml min⁻¹; IMS cell pressure, 0.55 mbar. The mass/charge ratio (*m/z*) scale was calibrated using aq. CsI cluster ions. CCS measurements were estimated using a calibration obtained by analysis of denatured proteins (cytochrome c, ubiquitin, and alcohol dehydrogenase) and peptides (tryptic digests of alcohol dehydrogenase and cytochrome c), with known CCSs obtained elsewhere from drift tube ion mobility measurements (15, 33). Data were processed using MassLynx v4.1 and Driftscope software supplied with a mass spectrometer.

Photo-induced covalent cross-linking

A 1:1 ratio of Aβ_{16–22}/Aβ^{*}_{16–22} or Aβ^{*}_{16–22}/Aβ₄₀ (40 μM total peptide concentration) in 100 mM ammonium bicarbonate buffer (pH 7.4) with a final concentration of 1% (v/v) DMSO was incubated in Eppendorf tubes for either 5 min or 24 hours. Samples were then irradiated for 30 s using a homebuilt light-emitting diode lamp at 365 nm, then removed, lyophilized overnight, taken up in HFIP for at least 2 hours, and vortexed to ensure that any aggregates were disrupted. HFIP was then removed under a stream of N₂, and the sample was resuspended in 50:50 (v/v) MeCN/H₂O + 0.05% formic acid to a final concentration of ~40 μM. Any cross-links were then analyzed using the method previously described and the ESI-IMS-MS system as described above (16).

DMD and PRIME20 force field

The simulation approach applied in this work is DMD, a fast alternative to traditional MD, in combination with the PRIME20 force field, a four-bead-per-residue coarse-grained protein model developed by the Hall group (44). In the PRIME20 model, each of the 20 different amino acids contains three backbone spheres (NH, C_αH, and CO) and one side-chain sphere (R) with a distinct hard sphere diameter (effective van der Waals radius) and distinct side chain-to-backbone distances (R-C_αH, R-NH, and R-CO). The backbone hydrogen bonding interaction is modeled as a directional square well potential. In the original PRIME20 force field, the potential function between any two side-chain beads on the 20 different amino acids (except glycine) is modeled as a single-well potential, containing 210 different square well widths and 19 different square well depths using the 5.5 Å heavy atom criteria. In this work, we follow Cheon's approach to apply a double-square well potential instead of the single-square well for side chain-side chain interaction (45). All the other nonbonded interactions are modeled as hard sphere interactions. A detailed description of the derivation of the geometric and energetic parameters of the PRIME20 model is given in our earlier work (46).

Simulation procedure

DMD/PRIME20 simulations were performed on the following systems: (i) six Aβ₄₀ monomeric peptides; (ii) six monomeric Aβ₄₀ peptides with six monomeric Aβ_{16–22} peptides; and (iii) six Aβ₄₀ monomeric peptides in the presence of preformed two, three, and four β-sheet Aβ_{16–22} protofilaments. The two, three, and four β-sheet Aβ_{16–22} protofilaments contain 21, 42, and 71 peptides, respectively. Each simulation was performed at two different total peptide concentrations (1 and 5 mM). Similar seeding simulations were performed in a previous work (45). The simulations were performed in the canonical ensemble (fixed number of particles, volume, and temperature). The reduced temperature was defined to be $T^* = k_B T / \epsilon_{HB}$, where the hydrogen bonding energy $\epsilon_{HB} = 12.47$ kJ/mol. The reduced temperature is related to real temperature by using the equation $T/K = 2288.46T^* - 115.79$. The reduced temperature T^* is chosen to be 0.20, which corresponds to a real temperature of 342 K. The system was maintained at a constant temperature by applying the Andersen thermostat. We performed 3 to 10 independent runs for each system.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/5/6/eaav8216/DC1>

General materials and methods for organic synthesis

Synthesis of *N*-Fmoc-protected TFMD-Phe

General materials and methods for Aβ_{16–22} solid-phase peptide synthesis

General materials and methods for HPLC purification

Analytical MS and HPLC data for synthetic peptides

General materials and methods for recombinant peptide synthesis

Additional characterization and analyses

CCS analysis of Aβ₄₀ in the presence and absence of Aβ_{16–22}

Scheme S1. Synthesis of TFMD-Phe.

Fig. S1. HRMS and analytical HPLC traces of Aβ_{16–22} and its variants.

Fig. S2. SEC trace of Aβ₄₀ indicates that there is a single peak, and ESI-IMS-MS indicates that in the gas phase Aβ₄₀ is largely monomeric.

Fig. S3. Supplementary ThT data.

Fig. S4. Supplementary negative-stain TEM images.

Fig. S5. Analysis of the CCS values for Aβ₄₀ in the absence or presence of Aβ_{16–22} over different IMS experiments.

Fig. S6. PIC analysis of 1:1 Aβ^{*}_{16–22}/Aβ₄₀ at 5 min and 24 hours.

Fig. S7. Plot of the average number of hydrogen bonding and side chain-side chain.

Table S1. The expected and observed m/z values for monomeric and oligomeric $A\beta_{40}$ in isolation and in the presence of a 1:1 ratio of $A\beta_{16-22}$.

Table S2. Assignments of each of the major peaks observed in fig. S6A.

Data file S1. MD snapshots as pdb files Fig. 1 $t = 0$.

Data file S2. MD snapshots as pdb files Fig. 1 $t = 104$.

Data file S3. MD snapshots as pdb files Fig. 1 $t = 230$.

Data file S4. MD snapshots as pdb files Fig. 1 $t = 621$.

Data file S5. MD snapshots as pdb files Fig. 6 $t = 0.29$.

Data file S6. MD snapshots as pdb files Fig. 6 $t = 1.16$.

Data file S7. MD snapshots as pdb files Fig. 6 $t = 1.93$.

Data file S8. MD snapshots as pdb files Fig. 6 $t = 7.7$.

Data file S9. MD snapshots as pdb files Fig. 6 $t = 29$.

Data file S10. MD snapshots as pdb files Fig. 6 $t = 77.7$.

REFERENCES AND NOTES

1. T. P. J. Knowles, M. Vendruscolo, C. M. Dobson, The amyloid state and its association with protein misfolding diseases. *Nat. Rev. Mol. Cell Biol.* **15**, 384–396 (2014).
2. L. Adler-Abramovich, E. Gazit, The physical properties of supramolecular peptide assemblies: From building block association to technological applications. *Chem. Soc. Rev.* **43**, 6881–6893 (2014).
3. M. G. Iadanza, M. P. Jackson, E. W. Hewitt, N. A. Ranson, S. Ranson, A new era for understanding amyloid structures and disease. *Nat. Rev. Mol. Cell Biol.* **19**, 755–773 (2018).
4. R. Kaye, E. Head, J. L. Thompson, T. McIntire, S. C. Milton, C. W. Cotman, C. G. Glabe, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* **300**, 486–489 (2003).
5. C. Haass, D. J. Selkoe, Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. *Nat. Rev. Mol. Cell Biol.* **8**, 101–112 (2007).
6. D. Eisenberg, M. Jucker, The amyloid state of proteins in human diseases. *Cell* **148**, 1188–1203 (2012).
7. S. I. A. Cohen, M. Vendruscolo, C. M. Dobson, T. P. J. Knowles, From macroscopic measurements to microscopic mechanisms of protein aggregation. *J. Mol. Biol.* **421**, 160–171 (2012).
8. W.-F. Xue, S. W. Homans, S. E. Radford, Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 8926–8931 (2008).
9. S. I. A. Cohen, S. Linse, L. M. Luheshi, E. Hellstrand, D. A. White, L. Rajah, D. E. Otzen, M. Vendruscolo, C. M. Dobson, T. P. J. Knowles, Proliferation of amyloid- β 42 aggregates occurs through a secondary nucleation mechanism. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 9758–9763 (2013).
10. G. Meisl, X. Yang, E. Hellstrand, B. Frohm, J. B. Kirkegaard, S. I. A. Cohen, C. M. Dobson, S. Linse, T. P. J. Knowles, Differences in nucleation behavior underlie the contrasting aggregation kinetics of the $A\beta_{40}$ and $A\beta_{42}$ peptides. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 9384–9389 (2014).
11. S. I. A. Cohen, R. Cukalevski, T. C. T. Michaels, A. Šarić, M. Törnquist, M. Vendruscolo, C. M. Dobson, A. K. Buell, T. P. J. Knowles, S. Linse, Distinct thermodynamic signatures of oligomer generation in the aggregation of the amyloid- β peptide. *Nat. Chem.* **10**, 523–531 (2018).
12. G. Fusco, S. W. Chen, P. T. F. Williamson, R. Cascella, M. Perni, J. A. Jarvis, C. Cecchi, M. Vendruscolo, F. Chiti, N. Cremades, L. Ying, C. M. Dobson, A. de Simone, Structural basis of membrane disruption and cellular toxicity by α -synuclein oligomers. *Science* **358**, 1440–1443 (2017).
13. J. A. Varela, M. Rodrigues, S. de, P. Flagmeier, S. Gandhi, C. M. Dobson, D. Klenerman, S. F. Lee, Optical structural analysis of individual α -synuclein oligomers. *Angew. Chem. Int. Ed.* **57**, 4886–4890 (2018).
14. S. L. Bernstein, N. F. Dupuis, N. D. Lazo, T. Wytenbach, M. M. Condrón, G. Bitan, D. B. Teplow, J. E. Shea, B. T. Ruotolo, C. V. Robinson, M. T. Bowers, Amyloid- β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. *Nat. Chem.* **1**, 326–331 (2009).
15. L. M. Young, L.-H. Tu, D. P. Raleigh, A. E. Ashcroft, S. E. Radford, Understanding co-polymerization in amyloid formation by direct observation of mixed oligomers. *Chem. Sci.* **8**, 5030–5040 (2017).
16. G. W. Preston, S. E. Radford, A. E. Ashcroft, A. J. Wilson, Covalent cross-linking within supramolecular peptide structures. *Anal. Chem.* **84**, 6790–6797 (2012).
17. W. Zheng, M.-Y. Tsai, M. Chen, P. G. Wolynes, Exploring the aggregation free energy landscape of the amyloid- β protein (1–40). *Proc. Natl. Acad. Sci. U.S.A.* **113**, 11835–11840 (2016).
18. T. Gurry, C. M. Stultz, Mechanism of amyloid- β fibril elongation. *Biochemistry* **53**, 6981–6991 (2014).
19. B. Barz, B. Strodel, Understanding amyloid- β oligomerization at the molecular level: The role of the fibril surface. *Chem. A Eur. J.* **22**, 8768–8772 (2016).
20. B. Barz, Q. Liao, B. Strodel, Pathways of amyloid- β aggregation depend on oligomer shape. *J. Am. Chem. Soc.* **140**, 319–327 (2017).
21. W. Qiang, W.-M. Yau, J.-X. Lu, J. Collinge, R. Tycko, Structural variation in amyloid- β fibrils from Alzheimer's disease clinical subtypes. *Nature* **541**, 217–221 (2017).
22. B. De Strooper, E. Karran, The cellular phase of Alzheimer's disease. *Cell* **164**, 603–615 (2016).
23. M. Törnquist, T. C. T. Michaels, K. Sanagavarapu, X. Yang, G. Meisl, S. I. A. Cohen, T. P. J. Knowles, S. Linse, Secondary nucleation in amyloid formation. *Chem. Commun.* **54**, 8667–8684 (2018).
24. R. Cukalevski, X. Yang, G. Meisl, U. Weininger, K. Bernfur, B. Frohm, T. P. J. Knowles, S. Linse, The $A\beta_{40}$ and $A\beta_{42}$ peptides self-assemble into separate homomolecular fibrils in binary mixtures but cross-react during primary nucleation. *Chem. Sci.* **6**, 4215–4233 (2015).
25. C. J. Sarell, P. G. Stockley, S. E. Radford, Assessing the causes and consequences of co-polymerization in amyloid formation. *Prión* **7**, 359–368 (2013).
26. M. Jucker, L. C. Walker, Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature* **501**, 45–51 (2013).
27. L. O. Tjernberg, J. Näslund, F. Lindqvist, J. Johansson, A. R. Karlström, J. Thyberg, L. Terenius, C. Nordstedt, Arrest of β -amyloid fibril formation by a pentapeptide ligand. *J. Biol. Chem.* **271**, 8545–8548 (1996).
28. J. J. Balbach, Y. Ishii, O. N. Antzutkin, R. D. Leapman, N. W. Rizzo, F. Dyda, J. Reed, R. Tycko, Amyloid fibril formation by $A\beta_{16-22}$, a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR. *Biochemistry* **39**, 13748–13759 (2000).
29. M. C. Hsieh, C. Liang, A. K. Mehta, D. G. Lynn, M. A. Grover, Multistep conformation selection in amyloid assembly. *J. Am. Chem. Soc.* **139**, 17007–17010 (2017).
30. S. A. Petty, S. M. Decatur, Experimental evidence for the reorganization of β -strands within aggregates of the $A\beta_{(16-22)}$ peptide. *J. Am. Chem. Soc.* **127**, 13488–13489 (2005).
31. F. T. Senguen, N. R. Lee, X. Gu, D. M. Ryan, T. M. Doran, E. A. Anderson, B. L. Nilsson, Probing aromatic, hydrophobic, and steric effects on the self-assembly of an amyloid- β fragment peptide. *Mol. BioSyst.* **7**, 486–496 (2011).
32. M. Cheon, I. Chang, C. K. Hall, Spontaneous formation of twisted $A\beta_{16-22}$ fibrils in large-scale molecular-dynamics simulations. *Biophys. J.* **101**, 2493–2501 (2011).
33. L. M. Young, R. A. Mahood, J. C. Saunders, L. H. Tu, D. P. Raleigh, S. E. Radford, A. E. Ashcroft, Insights into the consequences of co-polymerisation in the early stages of IAPP and $A\beta$ peptide assembly from mass spectrometry. *Analyst* **20**, 6990–6999 (2015).
34. M. Biancalana, S. Koide, Molecular mechanism of thioflavin-T binding to amyloid fibrils. *Biochim. Biophys. Acta* **1804**, 1405–1412 (2010).
35. K. Garai, C. Frieden, Quantitative analysis of the time course of $A\beta$ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled $A\beta$. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 3321–3326 (2013).
36. J.-X. Lu, W. Qiang, W. M. Yau, C. D. Schwieters, S. C. Meredith, R. Tycko, Molecular structure of β -amyloid fibrils in Alzheimer's disease brain tissue. *Cell* **154**, 1257–1268 (2013).
37. R. Aleksis, F. Oleskovs, K. Jaudzems, J. Pahnke, H. Biverstål, Structural studies of amyloid- β peptides: Unlocking the mechanism of aggregation and the associated toxicity. *Biochimie* **140**, 176–192 (2017).
38. N. Schwierz, C. V. Frost, P. L. Geissler, M. Zacharias, From $A\beta$ filament to fibril: Molecular mechanism of surface-activated secondary nucleation from all-atom MD simulations. *J. Phys. Chem. B* **121**, 671–682 (2017).
39. F. A. Aprile, P. Sormanni, M. Perni, P. Arosio, S. Linse, T. P. J. Knowles, C. M. Dobson, M. Vendruscolo, Selective targeting of primary and secondary nucleation pathways in $A\beta_{42}$ aggregation using a rational antibody scanning method. *Sci. Adv.* **3**, e1700488 (2017).
40. W. Qiang, W.-M. Yau, Y. Luo, M. P. Mattson, R. Tycko, Antiparallel β -sheet architecture in lowa-mutant β -amyloid fibrils. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 4443–4448 (2012).
41. D. P. Smith, J. Anderson, J. Plante, A. E. Ashcroft, S. E. Radford, A. J. Wilson, M. J. Parker, Trifluoromethyl diazirine: An effective photo-induced cross-linking probe for exploring amyloid formation. *Chem. Commun.* **2008**, 5728–5730 (2008).
42. D. M. Walsh, E. Thulin, A. M. Minogue, N. Gustavsson, E. Pang, D. B. Teplow, S. Linse, A facile method for expression and purification of the Alzheimer's disease-associated amyloid β -peptide. *FEBS J.* **276**, 1266–1281 (2009).
43. K. L. Stewart, E. Hughes, E. A. Yates, D. A. Middleton, S. E. Radford, Molecular origins of the compatibility between glycosaminoglycans and $A\beta_{40}$ amyloid fibrils. *J. Mol. Biol.* **429**, 2449–2462 (2017).
44. M. Cheon, I. Chang, C. K. Hall, Extending the PRIME model for protein aggregation to all 20 amino acids. *Proteins* **78**, 2950–2960 (2010).
45. M. Cheon, C. K. Hall, I. Chang, Structural conversion of $A\beta_{17-42}$ peptides from disordered oligomers to U-shape protofilaments via multiple kinetic pathways. *PLOS Comput. Biol.* **11**, e1004258 (2015).
46. M. Cheon, I. Chang, C. K. Hall, Influence of temperature on formation of perfect tau fragment fibrils using PRIME20/DMD simulations. *Protein Sci.* **21**, 1514–1527 (2012).

Acknowledgments: We thank M. Iadanza for help with taking and processing the EM images. We also thank N. Khan for excellent technical support and members of our laboratories for excellent discussions during the course of the work. **Funding:** This work was supported by NIH grant R01 EB006006 and, in part, by National Science Foundation (NSF) Research Triangle Materials Research Science and Engineering Centers (MRSEC) grant DMR-1121107, NSF grant CBET 581606, and EPSRC grants EP/N035267/1, EP/N013573/1, and EP/KO39292/1. S.E.R. acknowledges funding from the ERC (grant agreement number 322408) and the Wellcome Trust (204963). S.J.B. gratefully acknowledges BBSRC for PhD studentship grant BB/J014443/1. The EM was purchased with funding from the Wellcome Trust (108466/Z/15/Z and 094232/Z/10/Z). Y.W. and C.K.H. gratefully acknowledge the support of a Cheney Visiting Scholar Fellowship from University of Leeds. **Author contributions:** S.J.B. performed the experimental work; Y.W. performed simulations; K.L.S. performed expression and purification of A β ₄₀; S.E.R., C.K.H., and A.J.W. designed the research; S.J.B., Y.W., A.E.A., S.E.R., C.K.H., and

A.J.W. wrote the paper. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data available from authors upon request.

Submitted 24 October 2018

Accepted 15 May 2019

Published 21 June 2019

10.1126/sciadv.aav8216

Citation: S. J. Bunce, Y. Wang, K. L. Stewart, A. E. Ashcroft, S. E. Radford, C. K. Hall, A. J. Wilson, Molecular insights into the surface-catalyzed secondary nucleation of amyloid- β ₄₀ (A β ₄₀) by the peptide fragment A β ₁₆₋₂₂. *Sci. Adv.* **5**, eaav8216 (2019).

Molecular insights into the surface-catalyzed secondary nucleation of amyloid- β_{40} ($A\beta_{40}$) by the peptide fragment A β_{16-22}

Samuel J. Bunce, Yiming Wang, Katie L. Stewart, Alison E. Ashcroft, Sheena E. Radford, Carol K. Hall and Andrew J. Wilson

Sci Adv 5 (6), eaav8216.
DOI: 10.1126/sciadv.aav8216

ARTICLE TOOLS	http://advances.sciencemag.org/content/5/6/eaav8216
SUPPLEMENTARY MATERIALS	http://advances.sciencemag.org/content/suppl/2019/06/17/5.6.eaav8216.DC1
REFERENCES	This article cites 46 articles, 10 of which you can access for free http://advances.sciencemag.org/content/5/6/eaav8216#BIBL
PERMISSIONS	http://www.sciencemag.org/help/reprints-and-permissions

Use of this article is subject to the [Terms of Service](#)

Science Advances (ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. The title *Science Advances* is a registered trademark of AAAS.